Skip to main content
. 2021 Apr 12;13(8):1834. doi: 10.3390/cancers13081834

Figure 3.

Figure 3

Cancer-specific survival (CSS). Comparison between patients who experienced hematologic and/or acute organ toxicity ≥grade 3 and patients with toxicities <grade 3.